Invitae’s High-Stakes Financial Maneuvering: Dilution Might Not Be That Bad

Invitae Corporation (NVTA) faces significant challenges in addressing its liquidity concerns. The firm is exploring multiple strategies to stabilize its financial and operational footing. These strategies encompass potential capital raising, asset divestitures, strategic refocusing on core business and R&D activities, curtailment of capital spending, operating cost reductions, and managing debt commitments. The company’s current cash… Read More Invitae’s High-Stakes Financial Maneuvering: Dilution Might Not Be That Bad

A primer on the impact of gene therapies and CASGEVY on CRISPR AG and the industry

CASGEVY approval CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG (CRSP) and Vertex (VRTX) specifically designed for the treatment of sickle cell disease (SCD) in individuals aged 12 and older who experience frequent vaso-occlusive crises (VOCs). Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as the first FDA-approved… Read More A primer on the impact of gene therapies and CASGEVY on CRISPR AG and the industry